Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) EBIT Margin (2022 - 2025)

Historic EBIT Margin for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to 26.97%.

  • Axsome Therapeutics' EBIT Margin rose 328100.0% to 26.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 37.85%, marking a year-over-year increase of 526300.0%. This contributed to the annual value of 72.74% for FY2024, which is 129300.0% up from last year.
  • As of Q3 2025, Axsome Therapeutics' EBIT Margin stood at 26.97%, which was up 328100.0% from 24.47% recorded in Q2 2025.
  • Axsome Therapeutics' 5-year EBIT Margin high stood at 6.74% for Q1 2023, and its period low was 444.23% during Q2 2022.
  • Over the past 4 years, Axsome Therapeutics' median EBIT Margin value was 89.62% (recorded in 2024), while the average stood at 123.66%.
  • In the last 5 years, Axsome Therapeutics' EBIT Margin soared by 3049200bps in 2023 and then tumbled by -829600bps in 2024.
  • Quarter analysis of 4 years shows Axsome Therapeutics' EBIT Margin stood at 245.86% in 2022, then surged by 44bps to 137.39% in 2023, then surged by 55bps to 61.14% in 2024, then skyrocketed by 56bps to 26.97% in 2025.
  • Its last three reported values are 26.97% in Q3 2025, 24.47% for Q2 2025, and 46.91% during Q1 2025.